This is a promotional website developed by AstraZeneca and intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk.

Unlock the potential of targeting the PI3K/AKT pathway in HR+/HER2-negative aBC with TRUQAP plus fulvestrant1

TRUQAP plus fulvestrant is indicated for the treatment of adult patients with HR+/HER2-negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally aBC or mBC with one or more PIK3CA/AKT1/PTEN alterations following recurrence or progression on or after an ET.2,3

After treatment with ET ± CDK4/6i, an unmet need persists for patients with HR+/HER2-negative aBC with one or more PIK3CA/AKT1/PTEN alterations, as their prognosis remains poor.1

TRUQAP plus fulvestrant combination therapy targets oncogenic signalling driven by PI3K/AKT pathway activation.2,4

Discover the dual inhibition action

You could delay disease progression for longer with TRUQAP plus fulvestrant compared with placebo plus fulvestrant.1

 

CAPItello-291 was a Phase 3 randomised, double-blind trial of 708 patients with HR+/HER2-negative aBC that were pre-, peri- and post-menopausal women and men.1 Patients were randomly assigned in a 1:1 ratio to receive TRUQAP plus fulvestrant or placebo plus fulvestrant.1

In CAPItello-291, for patients with HR+/HER2-negative aBC and PIK3CA/AKT1/PTEN alterations, TRUQAP plus fulvestrant achieved a statistically significant improvement in mPFS compared with placebo plus fulvestrant.1*

 

Explore clinical trial data

Overactivation of the AKT pathway can occur in ~50% of patients with HR+/HER2-negative aBC. These patients could benefit from longer progression-free survival. Through biomarker testing, you can identify eligible patients for treatment with TRUQAP plus fulvestrant.1,2

 

Learn more about biomarker testing

 

*Patients with PIK3CA/AKT1/PTEN-altered tumours treated with TRUQAP plus fulvestrant (n=155) experienced statistically significantly longer mPFS: 7.3 months vs 3.1 months with placebo plus fulvestrant (n=134); HR 0.50, 95% CI: 0.38–0.65, P<0.001.1

When caring for people with breast cancer, we know how important it is for you to use treatments that have manageable side effects.

Data from 355 patients who received TRUQAP plus fulvestrant in CAPItello-291 showed that adverse events were mostly grade 1 or 2.2

The most common adverse events (occurring in ≥20% of patients) of any grade
that were reported in the TRUQAP plus fulvestrant group were:2
image-2 image-2
Learn more about potential adverse events

*Diarrhoea includes diarrhoea and frequent bowel movements.2
†Cutaneous events include butterfly rash, dermatitis, dermatitis exfoliative generalised, drug eruption, drug reaction with eosinophilia and systemic symptoms (DRESS), erythema, erythema multiforme, papule, rash, rash erythematous, rash follicular, rash macular, rash maculo-papular, rash papular, rash pruritic, skin reaction and toxic skin eruption.2
‡Fatigue includes asthenia, fatigue and malaise.2

HCP sitting with patient looking across the table

Explore dosing and monitoring of TRUQAP

Learn more about the manageable dosing schedule of TRUQAP plus fulvestrant, which can help patients adjust to their treatment.2

 

Learn more
TRUQAP patient booklet support guide

Resources for you and your patients

Our comprehensive resources help support you in prescribing TRUQAP plus fulvestrant. We also have dedicated patient materials to help reassure your patients throughout the treatment journey.

Discover resources

Get in touch with us

Find out more about TRUQAP plus fulvestrant from a

member of the AstraZeneca team.

Visit here

Sign up for more information 

Opt in to stay up to date on the latest promotional and non-promotional service and product information.

Join our mailing list

aBC=advanced breast cancer; AKT=serine/threonine protein kinase; AKT1=serine/threonine protein kinase 1; CDK4/6i=cyclin-dependent kinase 4/6 inhibitor; CI=confidence interval;
ET=endocrine therapy; HER2=human epidermal growth factor receptor 2; HR=hazard ratio; HR+=hormone receptor positive; IHC=immunohistochemistry; ISH=in situ hybridisation; mBC=metastatic breast cancer; mPFS=median progression-free survival; PI3K=phosphatidylinositol-3 kinase; PIK3CA=phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PTEN=phosphatase and tensin homologue.

  1. Turner NC, et al. N Engl J Med. 2023;388(22):2058–2070.
  2. TRUQAP (capivasertib) 160 mg and 200 mg. Summary of Product Characteristics.
  3. NICE TA1063. Available at: https://www.nice.org.uk/guidance/ta1063. Accessed April 2026.
  4. Miricescu D, et al. Int J Mol Sci. 2020;22(1):173.

GB-68397 | April 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.